Weight of the evidence in statin clinical trials: comparing the results.
This review of lipid-lowering trials looks at both the primary and secondary prevention of coronary heart disease. It also introduces evidence pointing toward the emerging importance of nonlipid risk factors in the pathogenesis of atherosclerosis. This review is designed to enhance the primary care physician's working knowledge of the evidence supporting the importance of LDL-C reduction and the central role of statin therapy in the reduction of the risk of coronary heart disease, as well as provide a greater understanding of emerging risk factors.
Clearfield
Michael B
MB
Department of Internal Medicine, University of North Texas Health Science Center at Fort Worth-Texas College of Medicine, 76107-2644, USA. mclearfi@hsc.unt.edu
D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000453:epidemiology / Q000235:genetics / Q000517:prevention & control*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000097:blood / Q000517:prevention & control; D018570:Risk Assessment; D016896:Treatment Outcome
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors